Adenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, as platforms for gene therapy and gene editing, as well as for oncology approaches, making them class leading agents in the gene-advanced therapies arena.
The fully updated and expanded third edition covers the basic biology of adenoviruses and highlights the potential use of adenoviral vectors for the treatment of disease, including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for veterinary applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine applications, and oncolytic adenoviruses for antitumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
1. Adenoviral Vectors for Gene Therapy - p. i 2. Cover image - p. i 3. Title page - p. i 4. Table of Contents - p. i 5. Copyright - p. iv 6. Contributors - p. xxi 7. Chapter 1 Structural biology of adenovirus - p. 1 8. Chapter 2 Adenovirus cell entry - p. 45 9. Chapter 3 Adenovirus replication - p. 75 10. Chapter 4 Adenoviral vector construction I: Mammalian systems - p. 99 11. Chapter 5 Adenoviral vector construction II: Bacterial systems - p. 131 12. Chapter 6 Adenoviral vector packaging cell lines - p. 149 13. Chapter 7 Purification of adenovirus - p. 173 14. Chapter 8 Innate immune response to adenovirus vectors following intravascular administration - p. 205 15. Chapter 9 Antibodies against adenoviruses - p. 243 16. Chapter 10 Methods to mitigate immune response - p. 275 17. Chapter 11 Xenogenic adenoviral vectors as vaccines - p. 309 18. Chapter 12 Adenoviral vector targeting - p. 365 19. Chapter 13 Systems of adenoviral gene transfer vectors moving into their fourth generation - p. 403 20. Chapter 14 Hybrid adenoviral vectors - p. 433 21. Chapter 15 Canine adenovirus - p. 447 22. Chapter 16 Oncolytic adenovirus: Challenges and advancements of clinical translation - p. 459 23. Chapter 17 Imaging analysis of adenovirus particles during the cell entry and intracellular trafficking - p. 501 24. Chapter 18 Adenovirus-based strategies for cancer vaccines - p. 546 25. Chapter 19 Adenoviral vaccines—Infectious disease - p. 573 26. Chapter 20 Adenoviral vaccines: COVID-19 - p. 643 27. Chapter 21 Adenovirus vectored veterinary vaccines - p. 657 28. Chapter 22 Utility of adenoviral vectors in animal models—CV disease - p. 687 29. Chapter 23 Utility of adenoviral vectors in animal models of human disease III: acquired diseases - p. 705 30. Chapter 24 Utility of adenoviral vectors in animal models of human disease: Genetic diseases - p. 727 31. Chapter 25 Adenoviral vectors for gene editing - p. 755 32. Chapter 26 Manufacturing and upscaling - p. 777 33. Chapter 27 Regulation of adenoviral vector-based therapies: A CBER/OTP perspective - p. 831 34. Index - p. 861
Adenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, as platforms for gene therapy and gene editing, as well as for oncology approaches, making them class leading agents in the gene-advanced therapies arena.
The fully updated and expanded third edition covers the basic biology of adenoviruses and highlights the potential use of adenoviral vectors for the treatment of disease, including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for veterinary applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine applications, and oncolytic adenoviruses for antitumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.
1. Adenoviral Vectors for Gene Therapy - p. i 2. Cover image - p. i 3. Title page - p. i 4. Table of Contents - p. i 5. Copyright - p. iv 6. Contributors - p. xxi 7. Chapter 1 Structural biology of adenovirus - p. 1 8. Chapter 2 Adenovirus cell entry - p. 45 9. Chapter 3 Adenovirus replication - p. 75 10. Chapter 4 Adenoviral vector construction I: Mammalian systems - p. 99 11. Chapter 5 Adenoviral vector construction II: Bacterial systems - p. 131 12. Chapter 6 Adenoviral vector packaging cell lines - p. 149 13. Chapter 7 Purification of adenovirus - p. 173 14. Chapter 8 Innate immune response to adenovirus vectors following intravascular administration - p. 205 15. Chapter 9 Antibodies against adenoviruses - p. 243 16. Chapter 10 Methods to mitigate immune response - p. 275 17. Chapter 11 Xenogenic adenoviral vectors as vaccines - p. 309 18. Chapter 12 Adenoviral vector targeting - p. 365 19. Chapter 13 Systems of adenoviral gene transfer vectors moving into their fourth generation - p. 403 20. Chapter 14 Hybrid adenoviral vectors - p. 433 21. Chapter 15 Canine adenovirus - p. 447 22. Chapter 16 Oncolytic adenovirus: Challenges and advancements of clinical translation - p. 459 23. Chapter 17 Imaging analysis of adenovirus particles during the cell entry and intracellular trafficking - p. 501 24. Chapter 18 Adenovirus-based strategies for cancer vaccines - p. 546 25. Chapter 19 Adenoviral vaccines—Infectious disease - p. 573 26. Chapter 20 Adenoviral vaccines: COVID-19 - p. 643 27. Chapter 21 Adenovirus vectored veterinary vaccines - p. 657 28. Chapter 22 Utility of adenoviral vectors in animal models—CV disease - p. 687 29. Chapter 23 Utility of adenoviral vectors in animal models of human disease III: acquired diseases - p. 705 30. Chapter 24 Utility of adenoviral vectors in animal models of human disease: Genetic diseases - p. 727 31. Chapter 25 Adenoviral vectors for gene editing - p. 755 32. Chapter 26 Manufacturing and upscaling - p. 777 33. Chapter 27 Regulation of adenoviral vector-based therapies: A CBER/OTP perspective - p. 831 34. Index - p. 861
